NCT03241914 is a Phase 2, PHASE3 clinical trial of Megestrol Acetate in Endometrial Neoplasm Malignant Stage I, sponsored by Fudan University.

Who is sponsoring NCT03241914?

NCT03241914 is sponsored by Fudan University.

What drugs are being tested in NCT03241914?

Interventions in NCT03241914: Megestrol Acetate, Levonorgestrel-releasing Intrauterine System(LNG-IUS).

What condition does NCT03241914 study?

NCT03241914 studies Endometrial Neoplasm Malignant Stage I.

Is NCT03241914 still recruiting?

NCT03241914 is currently completed. Last updated 20 November 2020.

Last reviewed 2020-11-20 · How we verify

NCT03241914

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer

Completed Phase 2, PHASE3 Last updated 20 November 2020

What this trial tests

Phase 2, PHASE3 trial testing Megestrol Acetate in Endometrial Neoplasm Malignant Stage I in 64 participants. Completed in 18 June 2020.

Timeline

4 July 2017

Primary endpoint
18 June 2020

18 June 2020

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	64
Start date	4 July 2017
Primary completion	18 June 2020
Estimated completion	18 June 2020
Sites	1 location across China

Drugs / interventions tested

Megestrol Acetate (MEGESTROL ACETATE) — full drug profile →
Levonorgestrel-releasing Intrauterine System(LNG-IUS)

Conditions studied

Endometrial Neoplasm Malignant Stage I — all drugs for Endometrial Neoplasm Malignant Stage I →

Sponsor

Fudan University

Who can join

Adults 18 to 45, female only, with Endometrial Neoplasm Malignant Stage I. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To see if megestrol acetate plus Levonorgestrel-releasing intrauterine system (LNG-IUS) will not be inferior to returning the endometrial tissue to a normal state than megestrol acetate alone in patients with early endometrial cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Fertility-sparing treatment in early endometrial cancer: current state and future strategies.
Obermair A, Baxter E, Brennan DJ, McAlpine JN, et al · · 2020 · cited 62× · PMID 32689770 · DOI 10.5468/ogs.19169
Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions.
Contreras NA, Sabadell J, Verdaguer P, Julià C, et al · · 2022 · cited 60× · PMID 35269674 · DOI 10.3390/ijms23052531
Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing Treatment (FST) Decision Making in Early Stage Endometrial Cancer (ES-EC): A Systematic Review.
Tanos P, Dimitriou S, Gullo G, Tanos V. · · 2022 · cited 46× · PMID 35269800 · DOI 10.3390/ijms23052653
The Perspectives of Fertility Preservation in Women with Endometrial Cancer.
Knez J, Al Mahdawi L, Takač I, Sobočan M. · · 2021 · cited 22× · PMID 33546293 · DOI 10.3390/cancers13040602
Fertility-preserving treatment in women with early endometrial cancer: the Chinese experience.
Wang Y, Yang JX. · · 2018 · cited 21× · PMID 30584372 · DOI 10.2147/cmar.s188087
Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: Can biomarkers predict response?
Dore M, Filoche S, Danielson K, Henry C. · · 2021 · cited 19× · PMID 33718563 · DOI 10.1016/j.gore.2021.100732
Asian Society of Gynecologic Oncology International Workshop 2018.
Kong TW, Ryu HS, Kim SC, Enomoto T, et al · · 2019 · cited 10× · PMID 30740961 · DOI 10.3802/jgo.2019.30.e39
Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914
Xu Z, Yang B, Guan J, Shan W, et al · · 2023 · cited 8× · PMID 36562136 · DOI 10.3802/jgo.2023.34.e32

Verify or expand the search:

Other trials of Megestrol Acetate

Trials testing the same drug.

NCT07436793 — Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial · Phase 2 · not yet recruiting
NCT07254416 — A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients · Phase 4 · not yet recruiting
NCT06998758 — Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC · Phase 3 · recruiting
NCT05538897 — Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recur · Phase 1, PHASE2 · active not recruiting
NCT05332483 — Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer · Phase 1 · terminated

Other recruiting trials for Endometrial Neoplasm Malignant Stage I

Currently open trials in the same condition.

NCT05247268 — Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer · Phase 2 · recruiting
NCT05945407 — Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer · NA · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03241914 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 20 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03241914.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing